"The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease."
Bolded for emphasis. I think you parsed out the critical grammar that's been in front of us since March. And as far as personnel happenings since March's press release? Hmmm. Just more reasons to be bullish. Exciting times we're about to experience!